Vancomycin-associated nephrotoxicity in adult medicine patients: Incidence, outcomes, and risk factors

Pharmacotherapy

Volumn 34, Issue 7, 2014, Pages 653-661

  Meaney, Calvin J ^a   Hynicka, Lauren M ^b,c   Tsoukleris, Mona G ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

infectious disease; internal medicine; nephrotoxicity; piperacillin tazobactam; vancomycin

Indexed keywords

CREATININE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; EOSINOPHILIA; EOSINOPHILURIA; FEMALE; HUMAN; INCIDENCE; LEUKOCYTE DISORDER; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; RENOGRAPHY; RETROSPECTIVE STUDY; SKIN INFECTION; TERTIARY CARE CENTER; VANCOMYCIN ASSOCIATED NEPHROTOXICITY; CHEMICALLY INDUCED; KIDNEY DISEASES; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84903827255     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1423     Document Type: Article

References (31)

1. Levine DP,. Vancomycin: a history. Clin Infect Dis 2006; 42: S5-12.
2. Rybak M, Lomaestro B, Rotschager J, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society ofAmerica, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 1: 82-98.
3. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG,. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010; 2: 182. e1-7.
4. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A,. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 19: 2138-44.
5. Cano EL, Haque NZ, Welch VL, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. Clin Ther 2012; 1: 149-57.
6. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL,. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 4: 507-14.
7. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 2011; 12: 5475-9.
8. Lodise TP, Lomaestro B, Graves J, Drusano GL,. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 4: 1330-6.
9. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A,. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68: 1243-55.
10. Malacarne P, Bergamasco S, Donadio C,. Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients. Chemotherapy 2006; 4: 178-84.
11. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB,. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010; 12: 1143-9.
12. Horey A, Mergenhagen KA, Mattappallil A,. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann Pharmacother 2012; 11: 1477-83.
13. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P,. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 4: R204-12.
14. Kellum JA, Bellomo R, Ronco C,. Definition and classification of acute kidney injury. Nephron Clin Pract 2008; 4: c182-7.
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kid Dis 2002; 39: S1-266.
16. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 1: 31-41.
17. National Institutes of Health On-Line BMI Calculator. 2013. Available from http://www.nhlbi.nih.gov/guidelines/obesity/BMI/bmicalc.htm. Accessed August 5, 2013.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new methods of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-83.
19. Charlson ME, Szatrowski TP, Peterson J, Gold J,. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-51.
20. Downs NJ, Neihart RE, Dolezal JM, Hodges GR,. Mild nephrotoxicity associated with vancomycin use. Arch Int Med 1989; 8: 1777-81.
21. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI,. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 12: 1673-81.
22. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E,. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41: S341-53.
23. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 2: 203-12.
24. Kullar R, Leonard SN, Davis SL, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 2011; 5: 441-8.
25. Hellwig T, Hammerquist R, Loecker B, Shields J,. Retrospective Evaluation of the Incidence of Vancomycin and/or Piperacillin-Tazobactam Induced Acute Renal Failure (Abstract). Crit Care Med 2011; 12: 79.
26. Min E, Box K, Lane J, et al. Acute Kidney Injury in Patients Recieving Concomitant Vancomycin and Piperacillin/Tazobactam (Abstract). Crit Care Med 2011; 12: 200.
27. Zeiler M, Mayhall G, Lee E,. Incidence of nephrotoxicity with concomitant vancomycin and piperacillin-tazobactam versus vancomycin alone or in combination with a carbapenem, aztreonam, or levofloxacin in adult patients (Abstract). Crit Care Med 2009; 12: A415.
28. Pruchnicki MC, Dasta JF,. Acute renal failure in hospitalized patients: part I. Ann Pharmacother 2002; 7-8: 1261-7.
29. Wong-Beringer A, Joo J, Tse E, Beringer P,. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 2: 95-101.
30. Naughton CA,. Drug-induced nephrotoxicity. Am Fam Physician 2008; 6: 743-50.
31. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A,. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother 2011; 7: 3278-83.